March 15, 2022 -- Applied DNA Sciences and Spindle Biotech have executed a nonbinding letter of intent (LOI) that outlines the terms of a collaborative research agreement to bring together Applied DNA's LinearDNA platform and Spindle Biotech's proprietary, high yield RNA manufacturing system, the companies said in a press release.
Under the terms of the agreement, the companies will investigate the feasibility of using the LinearDNA platform to produce chemically modified DNA templates for use in Spindle Biotech's system. The companies hope for a simplified, high yield, and 100% cell-free workflow.
The use of LinearDNA as an IVT template removes several complex manufacturing steps necessitated by plasmid DNA, the companies said. Following initial validation work, the companies said they will explore the commercialization of an mRNA production system.
No financial details were disclosed.